APA (7th ed.) Citation

M, K., ME, G., M, W., A, H., R, S., B, R., . . . W, F. (2018). A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors. Oncoimmunology, 7(8), e1450710. https://doi.org/10.1080/2162402X.2018.1450710

Chicago Style (17th ed.) Citation

M, Kebenko, et al. "A Multicenter Phase 1 Study of Solitomab (MT110, AMG 110), a Bispecific EpCAM/CD3 T-cell Engager (BiTE®) Antibody Construct, in Patients with Refractory Solid Tumors." Oncoimmunology 7, no. 8 (2018): e1450710. https://doi.org/10.1080/2162402X.2018.1450710.

MLA (9th ed.) Citation

M, Kebenko, et al. "A Multicenter Phase 1 Study of Solitomab (MT110, AMG 110), a Bispecific EpCAM/CD3 T-cell Engager (BiTE®) Antibody Construct, in Patients with Refractory Solid Tumors." Oncoimmunology, vol. 7, no. 8, 2018, p. e1450710, https://doi.org/10.1080/2162402X.2018.1450710.